
CAS 500538-94-3
:N1,N4-Bis[3-(1H-benzimidazol-2-yl)phényl]-1,4-benzènedicarboxamide
- N1,N4-Bis[3-(1H-benzimidazol-2-yl)phenyl]-1,4-benzenedicarboxamide
- NSC 61610
- 1,4-Benzenedicarboxamide, N,N′-bis[3-(1H-benzimidazol-2-yl)phenyl]-
- NCI 61610
- 1,4-Benzenedicarboxamide, N1,N4-bis[3-(1H-benzimidazol-2-yl)phenyl]-
NSC61610
CAS :NSC61610 is anti-inflammatory that activates PPARγ in vitro via LANCL2 and adenylate cyclase/cAMP-dependent pathways, thereby improving experimental colitis.Formule :C34H24N6O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :548.59NSC61610
CAS :NSC61610 is a regulatory molecule that is a cyclic peptide. It has shown activity index in the range of 1-2, which indicates that it is active against autoimmune diseases, oncostatin and cancer. NSC61610 also has antiviral resistance and bowel disease properties, as well as being active against infectious diseases like HIV. The structure of this compound consists of two hexapeptides: lysine-alanine-lysine and methionine-glycine-methionine. Synthetase activity has been observed in both prokaryotic and eukaryotic systems, so it can be synthesized by bacteria or animals. NSC61610 may be useful for the treatment of inflammatory bowel disease due to its ability to inhibit synthetase activity in cells of the intestinal mucosa. It also has anti-inflammatory effects due to inhibition of cyclooxygenase enzymes COX1 and COX2.
Formule :C34H24N6O2Degré de pureté :Min. 95%Masse moléculaire :548.6 g/mol

